Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca Compounds Get Malaria Screening

by Lisa M. Jarvis
July 5, 2010 | A version of this story appeared in Volume 88, Issue 27

AstraZeneca will open its compound library to Medicines for Malaria Venture, a nonprofit group working to speed the development of new malaria treatments. MMV has enlisted Vicky Avery of Australia’s Griffith University to screen the library’s 500,000 compounds against Plasmodium falciparum, the most lethal of the malaria parasites. Any promising compounds will be funneled to AstraZeneca’s R&D facility in Bangalore, India, for further exploration. AstraZeneca appears to be upping its commitment to neglected diseases: This spring, the firm teamed with the Global Alliance for TB Drug Development to create a joint portfolio of compounds active against tuberculosis.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.